In Vitro Diagnostic Market Insight: Continued Growth and Consolidation
The In Vitro Diagnostic market values established companies with regulatory approval and market traction. This is demonstrated by premiums paid for acquisitions of companies that offer the opportunity to quickly capture market share and IPOs of companies with significant revenues.
In Vitro Diagnostic Market Insight: Continued Growth and Consolidation
Market Insight: Craig Steger, Oded Ben-Joseph, PhD, MBA, Echoe M. Bouta, PhD
The In Vitro Diagnostic market values established companies with regulatory approval and market traction. This is demonstrated by premiums paid for acquisitions of companies that offer the opportunity to quickly capture market share and IPOs of companies with significant revenues.
Driven by a multitude of factors including the ageing population, increasing burden of chronic and infectious diseases, mounting demand for early diagnosis, emergence of personalized medicine and higher demand for testing in the developing world, the global In Vitro Diagnostics (IVD) market is projected to grow at 5.2% CAGR from $68 billion in 2018 to $88 billion in 2023. We examined recent IVD market dynamics between 2016 and Q3/2019 including financing events, merger and acquisitions (M&As) and initial public offerings (IPOs). We analyzed these dynamics to assess the overall activity of the segment to provide management teams and boards with a market-aligned perspective.
News
A Panic Letter and the Quiet Reset of American Biotech
This article examines the quiet but profound reset underway in U.S. biotech, triggered by a rare combination of forces: delayed or reduced federal funding, large pharma cutting mid-stage partnerships, and venture capital pulling back as exits evaporate. Based on insights from Dr. Stanislav Glezer, it reveals a market splitting in two — with capital chasing late-stage and very early assets while Phase 1–2 companies are stranded in the middle. The piece also exposes how government uncertainty, shrinking NIH support, and overlooked patient-behavior realities are forcing founders to rethink their entire company lifecycle. In today’s environment, survival requires new strategies, new geographies, and a deeper understanding of human factors that no protocol can fix.
Read MoreResources
Outcome Capital Life Science Market Pulse, October 2025
Outcome Capital Life Science Market Pulse October 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
